Q4 revenue consensus $6.38B. Danaher (DHR) announced that its President and CEO, Rainer Blair, will comment tomorrow on the company’s fourth quarter 2024 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT. For the fourth quarter 2024, estimated revenues are anticipated to increase in the low-single digit percent range year-over-year. Estimated non-GAAP core revenue for the fourth quarter of 2024 is expected to be essentially flat year-over-year, which would be above the company’s previously announced guidance of a low-single digit percent decline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher announces investment partnership in Innovaccer
- Danaher price target lowered to $285 from $305 at Citi
- Danaher price target lowered to $268 from $278 at Evercore ISI
- Pony AI, Thermo Fisher initiated: Wall Street’s top analyst calls
- Scotiabank starts coverage on large cap life science tools trio